Abstract Efficient and rhythmic cardiac contractions depend critically on the adequate and synchronized release of Ca 2? from the sarcoplasmic reticulum (SR) via ryanodine receptor Ca 2? release channels (RyR2) and its reuptake via sarco(endo)plasmic reticulum Ca 2? -ATPase (SERCA2a). It is well established that this orchestrated process becomes compromised in diabetes. What remain incompletely defined are the molecular mechanisms responsible for the dysregulation of RyR2 and SERCA2a in diabetes. Earlier, we found elevated levels of carbonyl adducts on RyR2 and SERCA2a isolated from hearts of type 1 diabetic rats and showed the presence of these posttranslational modifications compromised their functions. We also showed that these mono-and di-carbonyl reactive carbonyl species (RCS) do not indiscriminately react with all basic amino acid residues on RyR2 and SERCA2a; some residues are more susceptible to carbonylation (modification by RCS) than others. A key unresolved question in the field is which of the many RCS that are upregulated in the heart in diabetes chemically react with RyR2 and SERCA2a? This brief review introduces readers to the field of RCS and their roles in perturbing SR Ca 2? cycling in diabetes. It also provides new experimental evidence that not all RCS that are upregulated in the heart in diabetes chemically react with RyR2 and SERCA2a, methylglyoxal and glyoxal preferentially do.
Introduction
Managing cardiovascular complications arising from the epidemic of diabetes mellitus (DM) that started more than 40 years ago is undoubtedly one of the major health care challenges of twenty-first century. In the USA, 26 million individuals have diagnosed DM and *2 million new cases are expected every year forward [1] . The current annual cost to diagnose and treat DM in the USA is in excess of $175 billion, with[$70 billion directed primarily toward to treating chronic complications including blindness, renal failure, heart failure, and stroke [2] . Other developed countries also face similar challenges with about 8 % of their population afficted with DM [3, 4] . In emerging economies (e.g., some Middle Eastern and south Asian countries), the problem is even more severe with C20 % of their populations afficted with DM [5] . Therapeutic strategies involving lifestyle changes (more exercise and food management), glucose-and lipid-lowering drugs, and antihypertensives are widely available to slow the development and/or progression of cardiovascular complications in individuals with DM [6] [7] [8] [9] . Unfortunately, cardiovascular complications still persist. The ACCORD trial also reported that intensive glucose control using complex insulin strategies do not reduce mortality rates in patients with chronic/ long-term type 2 diabetes [10, 11] . With the diabetic population aging, there is an urgent need to better understand fundamental mechanisms that initiate cardiovascular complications so as to expand the armamentarium of drugs available to reduce morbidity and mortality. Of interest in our laboratory is the roles reactive carbonyl species (RCS) play in the pathogenesis of diabetic cardiomyopathy. Specifically, we are interested in the mechanisms by which RCS perturb sarcoplasmic reticulum (SR) Ca 2? cycling, trigger arrhythmias, and impair cardiac contractility.
Sarcoplasmic reticulum Ca 21 cycling and cardiac contraction
Excitation-contraction coupling is the process whereby membrane depolarization brings about myocyte contraction. Following an action potential, voltage-gated L-type Ca 2? channels on the invaginated T-tubule membranes open and allow the influx of a small amount of extracellular Ca 2? inside the myocyte [12] . This influxed Ca 2? traverses the dyad junction space and bind to multiple, juxtaposed ryanodine receptor Ca 2? release channels (RyR2), causing the release of a much larger amount of Ca 2? from the SR and the generation of a global Ca 2? transient; a process known as calcium-induced calcium-release, (CICR). The near tenfold rise in intracellular Ca 2? binds to troponin C, displacing it from actin, thereby allowing the formation of strong actin-myosin cross-bridges needed for myocyte contraction. Contraction is terminated when Ca 2? release from the sarcoplasmic reticulum (SR) is returned via sarco(endo)plasmic reticulum Ca 2? -ATPase (SERCA2a), and the influxed Ca 2? is extruded from the cell via the sodium Ca 2? exchanger (NCX) on the sarcolemmal membrane [13] . The integrity of Ca 2? cycling into and out of the SR dictates the strength of cardiac contraction and defects in this processes are disease causing. For example, premature activation of RyR2 will trigger delayed-afterdepolarization and arrhythmias and reduce the rate and force of cardiac contraction [14, 15] . Reductions in the activities of SERCA2a and NCX will elevate cytoplasmic Ca 2? which will prematurely activate RyR2 and trigger arrhythmias, reduce the amplitude of evoked Ca 2? transient, and slow rate and force of cardiac contraction. Furthermore, defects in SERCA2a and NCX will elevate cytoplasmic Ca 2? that will lead to unregulated activation of signal transduction cascades [16] . A reduction in SERCA2a activity will also lower the Ca 2? content inside the SR which will activate the endoplasmic reticulum (ER) stress response [17, 18] .
Numerous studies have reported significant changes in SR Ca 2? cycling in the diabetic heart, including reductions in rate and amplitude of evoked Ca 2? release from the SR, and a slowing in rate of removal of Ca 2? from the cytoplasm [19] [20] [21] [22] [23] [24] [25] . More detailed analyses of the evoked Ca 2? transients also revealed non-uniform (dyssynchronous) Ca 2? release from SR and alterations in spontaneous Ca 2? release from the SR [21, 24, 25] . Although it is accepted that these defects stem in part from changes in the activities of RyR2 and SERCA2a, specific molecular mechanisms responsible remain incompletely defined. General explanations for their altered activities include a reduction in steady-state level of protein and/or mRNA [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] . With respect to SERCA2a, changes in steady-state levels have been attributed to an increased O-GluNAcylation (O-linked N-acetylglucosamine) of its transcription factor Sp1, a reduction in thyroid hormone, and from an increased association with its intrinsic inhibitor protein, phospholamban (PLN) [34] [35] [36] [37] . Recent data from the laboratories of Cohen and Schöneich [38] suggest that increased oxidation at Cyst 674 (sulfonic acid adduct) may also lead to enhanced degradation of SERCA2. Studies have also reported changes in the amount of phosphorylation of RyR2 at Ser2808 (human)/Ser2809 (rabbit and rodents) and Ser2814 (human)/Ser2815 (rabbit and rodents) arising from altered activities of protein kinase A (PKA) and Ca 2? -calmodulin kinase II, respectively, and phosphatases [24, 25, 39, 40] . Another PKA-mediated phosphorylation site on RyR2, Ser2030, has been identified [41] , but its role in the pathogenesis of diabetic cardiomyopathy remains undefined. We also reported increased disulfide bonds on RyR2 in DM, but the identities of the cysteine residues involved have not been defined [42] . Recently, we purified RyR2 from hearts of rats with type 1 diabetes (T1D) under reducing and dephosphorylating conditions, and showed that its responsiveness to the intrinsic modulators (Ca 2? , ATP, cADP-ribose, Mg 2? ) was altered [43] . These novel findings led us to conclude that mechanisms other than changes in expression, disulfide bond formation between adjacent cysteine residues, and phosphorylation at Ser2808(9) and Ser2814(5) are likely responsible for RyR2 dysregulation in diabetes. These data also indicate that RyR2 in diabetic animals was phenotypically distinct from RyR2 in control animals. The latter is especially important from a drug development standpoint.
Cellular oxidants in diabetes
Hyperglycemia increases the production of two groups of cellular oxidants, reactive oxygen species (ROS), and reactive carbonyl species (RCS). ROS which includes superoxide anion, O -are generated from NAD(P)H oxidases, nitric oxide synthases, xanthine oxidases, and complex I and III of the mitochondrial electron transport chain [44, 45] . RCS are small electrophilic, mono-and di-carbonyl species (Fig. 1 ) that includes acrolein, N e carboxy(methyl)lysine, 3-deoxyglucosone, glyoxal (GO), 4-hydroxynonenal (4-HNE), malondialdehyde (MDA), and methylglyoxal (MGO). Unlike ROS that are generated mainly from the precursor superoxide anion (O 2
•-), RCS are diverse in chemical structures and are derived from multiple sources, including auto-oxidation of glucose and lipids, triose pathway fluxes, and from enzymes such as semicarbazide-sensitive amine oxidases and methylglyoxal synthase [46] [47] [48] [49] . RCS also have unique characteristics compared to ROS in that their half-lives are longer (min vs. ms), and they are uncharged molecules, allowing them to migrate distances far from their site of production [50] . Cellular levels of RCS are tightly regulated by several RCS-degrading enzymes including glutathione S-transferases (hGSTA4-4 and hGST5.8), aldose reductases, aldehyde dehydrogenases, and glyoxalases [51] [52] [53] [54] [55] .
The physiological roles for most RCS remain incompletely defined. What we know to date is that low concentrations (B10 lM) of 4-HNE play important roles in regulating cell growth, proliferation, differentiation, and apoptosis [56, 57] . Recent data suggest that acting as a GABA A agonist MGO may help to lower anxiety [58, 59] . What is clear is elevation in RCS is involved in the pathogenesis of several disease, including neurodegeneration, cancer, and diabetic complications [47, [60] [61] [62] [63] [64] . When produced in amounts that exceed the capacity of its degrading enzyme(s), RCS will react with susceptible basic amino acid residues on proteins to form carbonyl adducts ( Fig. 1, right panel) . Since there are no enzymes in mammalian cells that can break RCS adducts after they are formed on proteins, these adducts remain on the protein throughout its lifetime. For slowly turned over proteins, accumulations of carbonyl adducts will likely compromise their functions. To date, it is unclear whether non-enzymatic carbonylation serves as a signal for protein degradation, akin to metal-catalyzed carbonylation [65] .
Reactive carbonyl species and SR Ca 21 cycling defects
Earlier, we found higher levels of MGO adduct (argpyrimidine) on RyR2 and SERCA2a in hearts of rats with diabetic cardiomyopathy. We then showed using in vitro techniques that MGO can recapitulate in control myocytes, the alterations in SR Ca 2? cycling and alterations in contraction seen in diabetic myocytes [30, 66] . In lipid bilayer studies, MGO altered the gating and conductance of RyR2. In Ca 
The effects of MGO, GO, and 4-HNE on RyR2
To date, the role of other upregulated RCS in diabetes, including MDA, 4-HNE, and GO on the functioning of RyR2 and SERCA2a and pathogenesis of diabetic cardiomyopathy remain unclear. In our laboratory, a series of in vitro experiments were initiated employing [
3 H]ryanodine binding, lipid bilayer, and Ca 2? uptake assays, to establish rank order , 2 mM reduced glutathione, and 100 lM EGTA, 6.7 nM [ 3 H]ryanodine, pH 7.4) with varying concentrations of MGO (0-300 lM), GO (0-1,000 lM), and 4HNE (0-1,000 lM) and for 2 h at 37°C. After incubation, membranes were filtered, washed, and the amount of [ 3 H]ryanodine remaining on the filter paper was determined using liquid scintillation counting. Non-specific binding was determined simultaneously by incubating vesicles with 1 lM unlabeled ryanodine. Data shown represent mean ± SEM for four experiments performed using three different membrane preparations . MGO (0-50 lM) was then added to the cis chamber (1:250 dilution) and the effects on gating and conductance of the channels were recorded. b Mean ± SEM for n = 7 channels from three separate RyR2 preparations. Asterisk denotes significantly different from the absence of drug (0 lM) at p \ 0.05 potency for three of the major RCS, MGO, glyoxal GO, and 4-HNE. The procedures used for these assays are detailed elsewhere [30, 43, 66] . We also began using adduct-specific antibodies to determine relative levels of MGO, GO, 4-HNE, and MDA adducts on RyR2 and SERCA2a in hearts from control, diabetic, and drug-treated diabetic animals [70] , to gain insights into the role these RCS are playing in the pathophysiology of the disease.
The 
3 H]ryanodine) and K L of 1.2 nM for RyR2, the K i of MGO was 47.2 ± 6.5 lM, 150.5 ± 7.3 lM for GO, and 342.1 ± 18.0 lM for 4-HNE.
To assess the functional consequences, lipid bilayer assays were conducted, adding MGO, GO, and 4-HNE to the cis chamber (equivalent to the cytoplasm) and assessing their effects on gating and conductance of RyR2. The procedures for this assay are detailed in recent studies [43, 66] . Earlier, we showed that MGO increases the openness of an already opened RyR2 [66] . In this study, experiments conditions were manipulated to significantly reduce the P o of RyR2, that is, make it near closed [43] and assess whether MGO can also activate these closed channels. Figure 3 shows that MGO can also significantly increase the P o of low-activity RyR2. The increase in P o by low .
concentrations from MGO resulted from increases in the dwell time in the opened state ([threefold) and the number of transitions from the closed to the opened state. MGO also reduced the conductance of RyR2 by about 20 % (G = 667 ± 40 pS before and 540 ± 20 pS after MGO treatment, see Fig. 3a , dotted lines). As shown earlier, high concentrations of MGO also reduced P o of RyR2 [66] . GO also dose dependently increased and then decreased the P o of RyR2 (Fig. 4) . But unlike MGO, it did not alter the conductance of RyR2 (G = 662 ± 26 pS before and 645 ± 30 pS after GO treatment). Similar to MGO and GO, low concentrations of 4-HNE (B10 lM) increased the P o of RyR2 by modulating the dwell time in the opened state and the number of transitions from the closed to the opened state (Fig. 5) . Concentration of 4-HNE [ 10 lM decreased the P o of RyR2. 4-HNE also did not alter the conductance of RyR2. Rank order potencies for channel opening and closing were MGO * GO [ 4HNE and MGO [ GO [ 4HNE, respectively. It should be pointed out that although these were acute studies, they do provide valuable insights into the effects of these RCS on the activity of RyR2.
Effects of MGO, GO, and 4-HNE SERCA2a activity
Pre-incubation of SERCA2a with a low dose of MGO (1 lM) potentiated its ability to transport Ca 2? while higher concentrations dose dependently reduced its ability to transport Ca 2? (Fig. 6 ). The concentration of MGO that inhibited SERCA2a activity by 50 %, (EC 50 inhibition ) was 15.6 ± 7.4 lM. GO and 4-HNE also reduced the ability of SERCA2a to transport Ca 2? , with EC 50 inhibition of 55.6 ± 5.4 lM and 350.6 ± 9.6 lM, respectively (Fig. 6) . Rank order potency for the inhibition of SERCA2a was MGO [ GO ) 4-HNE.
Amounts of MGO (argpyrimidine), GO, 4-HNE, and MDA adducts on RyR2 and SERCA2a in diabetic rat heart
While in vitro assays can provide insights into the actions of RCS on the function of RyR2 and SERCA2a, they do not provide information on which of the RCS react with . For this, phosphatidylethanolamine, phosphatidylserine, and phosphatidylcholine in a ratio of 5:3:2 (35 mg/mL of lipid) in n-decane were painted across a 200-lm-diameter hole of the bilayer cup. Single RyR2 channel was then fused to the bilayer and basal channel activity was recorded in symmetric KCl buffer solution (0.25 mM KCl, 20 mM K-Hepes, pH 7.4) with 2.0 lM cis (cytoplasmic) Ca 2? . 4-HNE (0-50 lM) was then added to the cis chamber (1:250 dilution) and the effects on gating and conductance of the channels were recorded. b Mean ± SEM for n = 6 channels from three separate RyR2 preparations. Asterisk denotes significantly different from the absence of drug (0 lM) at p \ 0.05 and impair the functions of these proteins in vivo. To address this, Western blot analyses employing adductspecific antibodies were used to compare relative amounts of MGO GO, 4-HNE, and MDA adducts on RyR2 and SERCA2 in hearts from control and diabetic rat hearts. In this study, RyR2 from streptozotocin-induced diabetic hearts (8-weeks) contained[twofold higher levels of MGO (argpyrimidine) and GO adducts compared to RyR2 from controls (Fig. 7a) . MGO (argpyrimidine) adducts were also twofold higher on SERCA2a isolated from hearts with diabetic cardiomyopathy compared with SERCA2a from control hearts. 4-HNE and MDA adducts were not detected on RyR2 and SERCA2a from control or streptozotocininduced diabetic rat hearts using two commercially available 4-HNE (EMD Millipore, Billerica, MA, catalogue#-AB5605 and Santa Cruz Biotechnology Inc, Dallas TX, catalogue#-sc-130083) and MDA (EMD Millipore, Billerica, MA, catalogue#-442730-50UL and Santa Cruz Biotechnology Inc, Dallas TX, catalogue#-sc-130087) antibodies. The lack of immunoreactive MDA and 4-HNE adducts was not due to the absence of RyR2 and SERCA2a proteins in our SR preparations, since these proteins were readily detected using RyR2 and SERCA2a antibodies (Fig. 7a, b, 5th autoradiogram down). In a recent study, we showed that these antibodies detected MDA and 4-HNE adducts on proteins of M w between 30 and 80 kDa in our SR preparation [70] . , and 10 mM potassium oxalate) and divided into 3 9 500 ll aliquots. One aliquot was incubated with a SERCA inhibitor cocktail (10 lM thapsigargin, 100 lM ammonium molybdate, 0.05 lg bafilomycin) for 30 min at 37°C, a second aliquot was incubated with either MGO, GO, and 4-HNE (0-600 lM) for 30 min at 37°C, and the third aliquot remained untreated but was also incubated for 30 min at 37°C. Ca 2? uptake was initiated in each aliquot by the addition of 1 mM ATP (Na 2 ATP) and at various times, membranes were cold-filtered and washed. The amount of 45 
Ca
2? remaining on the filter papers was measured. Ca 2? uptake via SERCA was derived from subtracting uptake in the absence of drug from that in the presence of the SERCA inhibitor cocktail
Perspective
It is becoming clearer that therapeutic strategies beyond glucose-lowering, lipid-lowering, and anti-hypertensives are urgently needed to help reduce and/or reverse the incidence of cardiovascular complications, in individuals with DM. Along these lines, two therapeutic approaches are receiving significant attention: reducing oxidative stress and inflammation [72] . As mentioned above, hyperglycemia induces two groups of cellular oxidants, ROS and RCS. To date, ROS scavengers (vitamin E, vitamin C, and beta-carotene) have only minimally improved cardiovascular outcomes in patients with DM [73, 74] . A possible reason for this is that the antioxidants used thus far in clinical trials may not have gained access to the sites where ROS are generated. Antioxidants and enzymes that degrade ROS are currently being nano-formulated in an attempt to target these agents into various cellular components [75] . Pharmacologic strategies to break carbonyl adducts after they are formed on proteins, such as alagebrium (ALT-711), have also only minimally improved cardiovascular functions in patients with heart failure [76] . One reason why alagebrium may have been less successful in clinical trials is that it converts the charge on basic amino acid residues of proteins from positive to negative after removing the carbonyl adduct, the equivalent of genetic mutations [77] . Data from several laboratories including ours have recently shown that MGO is a potent inducer of ROS [66, 78] . Specifically, we showed that within seconds after exposure to MGO, spontaneous Ca 2? sparks increased in rat ventricular myocytes and this was followed by Ca 2? waves (*40-45 s). About 10 min thereafter, mitochondrial ROS production also increased. The mechanisms by which MGO increase mitochondrial ROS production are not well delineated. What we know to date, using the mitochondria-targeted Ca 2? -sensitive dye, Rhod-2, and the mitochondria-targeted dye Mitotracker Green TM , is that in addition to increasing cytoplasmic Ca 2? , MGO also increases mitochondria Ca 2? in rat ventricular myocytes, *45 s after exposure (Fig. 8) . Since mitochondria are the principal source of ROS in cells, these new findings suggest that removal and/or lowering of RCS would not only prevent the formation of adducts on proteins but also lower ROS production inside cells.
The availability of high-affinity antibodies against specific RCS adducts allowed us the opportunity to begin to address this question of which of the many RCS that are upregulated are responsible for perturbation in SR Ca 2? cycling and impairing cardiac contraction seen in chronic diabetes. The principal conclusion from the new data presented is that not all RCS that are upregulated in the heart in diabetes are likely to perturb SR Ca 2? cycling. Of the four RCS investigated, only two, MGO and GO, chemically react with and form adducts on RyR2 and SERCA2a in the streptozotocin-induced rat model of type 1 diabetes. The reasons why glucose-generated MGO and glucose/ lipid-generated GO preferentially react with RyR2 and SERCA2a and not lipid-derived 4-HNE and MDA is not clear at this time. However, several explanations are likely.
First, greater than 70 % of the ATP needed for cardiac functioning is derived from beta-oxidation of free fatty acids (FFAs) [79, 80] . This would suggest that the heart has an efficient detoxification system to rid itself of RCS derived from lipid metabolites. Whether organs, like liver and skeletal muscles that use glucose/pyruvate as its primary energy, have a detoxification systems that are slanted toward removing glucose-derived RCS and would therefore be more susceptible to lipid-derived RCS are also not known at this time. Second, our data are consistent with the notion that some RCS are inherently more reactive (potent) than others. In this study, we found that the di-carbonyl MGO and GO preferentially reacted with RyR2 and SERCA2 than the MDA and 4-NHE. Although MDA is dicarbonyl, one reason why it may not have reacted is that rapid enolizes at physiological pHs' [81, 82] to the less reactive enol which is a mono-carbonyl like 4-HNE. A third reason may be related to where in the cell MGO, GO, 4-HNE, and MDA are generated, and whether the enzymes that degrade are up/down-regulated. In myocytes, 4-HNE and MDA are generated from the oxidation of polyunsaturated fatty acids/lipids on the plasmamembrane, within mitochondria and in the cytoplasm by ROS [47, 83, 84] . They are also generated from increased prostaglandin, Fig. 7 Relative levels of MGO, GO, 4-HNE, and MDA adducts on RyR2 and SERCA2a. SR membranes from control hearts and diabetic rat hearts with established cardiomyopathy (60 lg) were solubilized in gel dissociation medium and electrophoresed on Criterion 4-15 % gradient Tris-glycine polyacrylamide gels (Bio-Rad Technologies Inc. Burlingame CA) for 210 min at 150 V. At the end of the electrophoresis, proteins were transferred onto polyvinylidene difluoride membranes (Millipore, Billerica, MA) at 100 mA, 16 h at 4°C using a semidry electroblotter (Owl Scientific Inc., Woburn, MA) using CAPS buffer (10 mM cyclohexylamino-1-propanesulfonic acid/ 0.01 % SDS in 10 % methanol, pH 9.0). Membranes were then blocked with 5 % skinned milk and Western blots were performed using adduct-specific antibodies to determine relative levels of MGO (argpyrimidine), glyoxal, MDA, and 4HNE adducts on RyR2 and SERCA2a from control and diabetic rat hearts. a Representative autoradiograms showing relative levels of MGO, GO, 4-HNE, and MDA adduct on RyR2 protein isolated from the hearts of control (C) and diabetic rat with cardiomyopathy (D). b-actin is also shown. Graph below shows mean ± SEM from n C 4 experiments. Asterisk denotes significantly different control at p \ 0.05. b representative autoradiograms showing relative levels of MGO, GO, 4-HNE, and MDA adduct on SERCA2a protein isolated from the hearts of control (C) and diabetic rat with cardiomyopathy (D). b-actin is also shown. Graph shows mean ± SEM from n C 4 experiments. Asterisk denotes significantly different control at p \ 0.05 thromboxane, and arachidonic acid biosynthesis [85, 86] . What is not well delineated is what fraction of the total 4-HNE and MDA generated inside the cell are derived from each pathway. Increases in expression and activities of aldose reductases and glutathione S-transferases (GSTA4-4 and GST5.8), major enzymes that degrade 4-HNE in diabetes, may also help explain the absence of 4-HNE adducts on RyR2 and SERCA2a [54] . Fourth, MGO and GO are generated throughout the cytoplasm from a variety of sources. Glyoxalase I (Glo-1), the principal enzyme that degrades MGO and GO [53] , is also upregulated in diabetic myocytes [30] and its cofactor reduced glutathione is lowered [87] . This may help explain why MGO (argpyrimidine) and GO adducts are formed on RyR2 and SERCA2a in diabetes.
The new data presented in this short review are not without limitations. Only two commercially available antibodies against MDA and 4-HNE were used according to the manufacturers' suggestions (1:000 dilution and 1:500 dilutions) employing 60 lg of SR membrane proteins from control and diabetic rat hearts per gel lane, incubated at 4°C for 16-20 h. In future studies, other commercially available antibodies will be used along with other approaches such as mass spectrometry. The latter was not pursued earlier since we reasoned that if we could not detect 4-HNE and MDA adducts immunologically, it also be very challenging to detect them using mass spectrometry, especially for very large proteins like RyR2. Another major question that must be addressed is whether MGO, GO, 4-HNE, and MDA adducts are formed on RyR2 and SERCA2a in other models of diabetes.
Conclusion
It is becoming clearer that RCS are covalently reacting with cellular proteins in DM and altering their functions. These RCS did not indiscriminately react with all available basic amino acid residues on proteins. Some residues are more susceptible to carbonylation than others, presumably because of the electronic environment of these residues. It is known that basic residues with low pKa's are more likely to undergo carbonylation than residues with higher pK a s, since a higher fraction of the low pK a residue will exist in a deprotonated state at a physiological pH of 7.4. New data presented in this review show that not all RCS that are upregulated in diabetes covalently react with every protein inside cells. In the case of cardiac RyR2 and SERCA2a, they are preferentially modified by MGO and GO and not by MDA and 4-HNE. The reason for this selectivity is unclear at this time, but several reasons have been discussed. New data are also emerging indicating that RCS, in particular MGO, perturbs intracellular Ca 2? homeostasis and increase oxidative stress by increasing mitochondrial ROS production inside cells. At this time, it is not clear whether these events are preceding posttranslational modifications, that is, whether RCS are acting as agonist/ antagonist at RyR2 and SERCA2 as well. What is clear at this time is that targeting RCS will not only prevent carbonylation/dysfunction of proteins inside cells, but will also minimize disturbance in intracellular Ca 2? homeostasis and reduce ROS production. Knowing this information is especially important since targeting only those RCS that are involved in disease pathogenesis would be advantageous over targeting all RCS in the diabetic heart.
